Page 3 - துணை ப்ரெஸிடெஂட் தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Lecanemab (BAN2401) Phase 2b study in early Alzheimer s disease published in peer-reviewed journal, Alzheimer s Research & Therapy
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Lecanemab (BAN2401) Phase 2b study in early Alzheimer s disease published in peer-reviewed journal, Alzheimer s Research & Therapy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Börse Express - DGAP-News: CureVac veröffentlicht Finanzergebnisse des vierten Quartals sowie des Gesamtjahres 2020 und informiert über seine Geschäftsentwicklung (deutsch)
boerse-express.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-express.com Daily Mail and Mail on Sunday newspapers.
Patrick Salois Appointed Vice-President, Sales and Operations of La Presse
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021
News provided by
Share this article
Share this article
STOCKHOLM, March 15, 2021 /PRNewswire/ BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the company and its partner Eisai at the 15th International Conference on Alzheimer s and Parkinson s Diseases and related neurological disorders, AD/PD™. The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down s syndrome with signs of functional or cognitive deterioration. Preliminary results presented from the ongoing open-label extension of the Phase 2b study in early Alzheimer s disease continue to support the effect of lecanemab on brain amyloid levels.